NCT01569204View on ClinicalTrials.gov

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

December 31, 2017

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Etoposide

DRUG

Cyclophosphamide

DRUG

Doxorubicin

DRUG

Prednisone

DRUG

Procarbazine

DRUG

Dexamethasone

DRUG

Dacarbazine

DRUG

Brentuximab Vedotin

Trial Locations (1)

Unknown

1st Dept. of Medicine, Cologne University Hospital, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER

NCT01569204 - Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter